Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma

被引：30

作者：

Segers, K

Backhovens, H

Kumar-Singh, S

DeVoecht, J

Ramael, M

Van Broeckhoven, C

VanMarck, E

机构：

[1] UNIV ANTWERP, DEPT MED, PATHOL LAB, B-2610 ANTWERP, BELGIUM

[2] UNIV ANTWERP, DEPT BIOCHEM, BORN BUNGE FDN, NEUROGENET LAB, B-2610 ANTWERP, BELGIUM

来源：

VIRCHOWS ARCHIV | 1995年 / 427卷 / 04期

关键词：

malignant mesothelioma; p53; mdm2; automated sequencing;

D O I：

10.1007/BF00199393

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Previous immunohistochemical studies on malignant mesothelioma with antibodies recognizing both the wild and the mutant types of the p53 protein have shown immunoreactivity in 25-70% of cases. This study was designed to determine whether there is immunoreactivity for p53 and mdm2 protein in malignant mesothelioma and to correlate p53 expression with the detection of mutations in p53 at DNA level. In 10 of 15 cases there was immunoreactivity for p53. In 6 of these cases immunoreactivity for mdm2 was also detected. In one p53-immunonegative case, a mutation of the p53 gene resulting in a stop codon was found. These results suggest that mdm2 might be involved in the inhibition of p53 in malignant mesothelioma, Also, these data suggest the existence of other proteins than mdm2 that may associate with p53.

引用

页码：431 / 436

页数：6

共 33 条

[1]

Barnes D.M., Hanby A.M., Gillet C.E., Mohammed S., Hodgson S., Bobrow L.G., Leigh I.M., Purkis T., MacGeoch C., Spurr N.K., Bartek J., Vojtesek B., Picksley S.M., Lane D.P., Abnormal expression of wild type p53 protein in normal cells of a cancer family patient, Lancet, 340, pp. 259-263, (1992)

[2]

Battifora H., p53 immunohistochemistry: a word of caution, Hum Pathol, 25, pp. 435-437, (1994)

[3]

Blin N., Stafford D.M., A general method for the isolation of high molecular-weight DNA from eukaryotes, Nucleic Acids Res, 3, pp. 2303-2308, (1976)

[4]

Cagle P.T., Brown R.W., Lebowitz R.M., p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens, Hum Pathol, 25, pp. 443-448, (1994)

[5]

Callahan R., Cropp C.S., Merlo G.R., Liscia D.S., Cappa A.P., Lidereau R., Somatic mutations and human breast cancer. A status report, Cancer, 69, pp. 1582-1588, (1992)

[6]

Chang F., Syrjanen S., Tervahauta A., Syrjanen K., Tumorigenesis associated with the p53 tumour suppressor gene, Br J Cancer, 68, pp. 653-661, (1993)

[7]

Ciechanover A., DiGiuseppe J.A., Bercovich B., Orian A., Richter J.D., Schwartz A., Brodeur G.M., Degradiation of nuclear oncoproteins by the ubiquitin system in vitro, Proc Natl Acad Sci USA, 88, pp. 139-143, (1991)

[8]

Cordon-Cardo C., Latres E., Drobnjak M., Oliva, Pollack D., Woodruff J.M., Marechal V., Chen J., Brennan F.M., Levine A.J., Molecular abnormalities of mdm2 and p53 genes in adult soft tissue carcinoma, Cancer Res, 54, pp. 794-799, (1994)

[9]

Cote R.J., Jhanwar S.C., Novick S., Pellicer A., Genetic alterations of the p53 gene are a feature of malignant mesotheliomas, Cancer Res, 51, pp. 5410-5416, (1991)

[10]

De Pangher, Brollo A., Franceschi S., De Matthaeis M., Talamini R., Bianchi C., Prognostic factors of malignant mesothelioma of the pleura, Cancer, 72, pp. 410-417, (1993)

← 1 2 3 4 →